Skip to main content
Erschienen in: Pathology & Oncology Research 4/2016

26.05.2016 | Original Article

Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas

verfasst von: Sarah Benezech, Sylvie Chabaud, Fanny Chambon, Frédérique Dijoud, Franck Chotel, Perrine Marec-Berard

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Metastatic status, histologic response, and quality of surgical resection are prognostic factors for osteosarcomas. Pathology reports sometimes describe peritumoral vascular invasion on surgical specimens after neoadjuvant chemotherapy but their prognostic significance as an independent parameter has never been reported. The aim of this study was to evaluate how the presence of this peritumoral vascular invasion could influence survival. We retrospectively analyzed histology, demographics, and outcomes of pediatric patients treated for osteosarcoma in our institutions between January 2007 and December 2012. A single pathologist analyzed the resection specimens after neoadjuvant chemotherapy. Fifty-one osteosarcomas were diagnosed over a 6-year period; nine had metastatic disease at diagnosis. Surgery was performed after neoadjuvant chemotherapy in all cases. We identified peritumoral vascular invasion in the surgical specimens in 15 cases. Two-year event-free survival (EFS) was 78 % (CI95%[64;93]) for patients without vascular invasion versus 48 % (CI95% [21;75]) in patients with vascular invasion, and 2-year overall survival (OS) was 94 % (CI95%[86;100]) for those without vascular invasion versus 79 % (CI95%[57;100]) for others. Multivariate analysis demonstrated correlation of metastatic status and presence of vascular invasion with survival. The histopathological description of peritumoral vascular invasion in surgical specimens of osteosarcoma after neoadjuvant chemotherapy can be considered a prognostic factor and could indicate modification of the postoperative therapeutic strategy.
Literatur
1.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefPubMed Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776–790CrossRefPubMed
2.
Zurück zum Zitat Merimsky O, Isakov J, Kollender Y, Nirkin A, Inbar M, Meller I. Vascular invasion in high grade sarcoma of the extremity is associated with short overall survival. Oncol Rep n.d.1998; 5:985–9. Merimsky O, Isakov J, Kollender Y, Nirkin A, Inbar M, Meller I. Vascular invasion in high grade sarcoma of the extremity is associated with short overall survival. Oncol Rep n.d.1998; 5:985–9.
3.
Zurück zum Zitat Le Deley M-C, Guinebretière J-M, Gentet J-C, Pacquement H, Pichon F, Marec-Bérard P, et al. (2007) SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752–761. doi:10.1016/j.ejca.2006.10.023 CrossRefPubMed Le Deley M-C, Guinebretière J-M, Gentet J-C, Pacquement H, Pichon F, Marec-Bérard P, et al. (2007) SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 43:752–761. doi:10.​1016/​j.​ejca.​2006.​10.​023 CrossRefPubMed
4.
Zurück zum Zitat Marroum MC, Huvos AG, Rosen G (1977) Pathologic aspects of chemotherapy response in the treatment of osteogenic sarcoma. An analysis of two cases. Oncology 34:273–280CrossRefPubMed Marroum MC, Huvos AG, Rosen G (1977) Pathologic aspects of chemotherapy response in the treatment of osteogenic sarcoma. An analysis of two cases. Oncology 34:273–280CrossRefPubMed
6.
Zurück zum Zitat Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II analysis and examples BrJCancer 35:1–39 Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II analysis and examples BrJCancer 35:1–39
7.
Zurück zum Zitat Cox DR (1972) Regression models and life tables. J R Stat Soc Ser B 34:187–220 Cox DR (1972) Regression models and life tables. J R Stat Soc Ser B 34:187–220
8.
Zurück zum Zitat Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, et al. (1987) Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children’s hospital - study III. J Clin Oncol 5:1178–1184PubMed Goorin AM, Perez-Atayde A, Gebhardt M, Andersen JW, Wilkinson RH, Delorey MJ, et al. (1987) Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children’s hospital - study III. J Clin Oncol 5:1178–1184PubMed
9.
Zurück zum Zitat Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s cancer group. J Clin Oncol 15:76–84PubMed Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, et al. (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s cancer group. J Clin Oncol 15:76–84PubMed
10.
12.
Zurück zum Zitat Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431PubMed Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12:423–431PubMed
13.
Zurück zum Zitat Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230CrossRefPubMed Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221–1230CrossRefPubMed
14.
Zurück zum Zitat Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, et al. (2003) Scandinavian sarcoma group osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488–494CrossRefPubMed Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O, et al. (2003) Scandinavian sarcoma group osteosarcoma study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488–494CrossRefPubMed
15.
Zurück zum Zitat Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 2:617–624PubMed Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, et al. (1984) Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 2:617–624PubMed
16.
Zurück zum Zitat Juergens H, Kosloff C, Nirenberg A, Mehta BM, Huvos AG, Rosen G (1981) Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr 221–6 Juergens H, Kosloff C, Nirenberg A, Mehta BM, Huvos AG, Rosen G (1981) Prognostic factors in the response of primary osteogenic sarcoma to preoperative chemotherapy (high-dose methotrexate with citrovorum factor). Natl Cancer Inst Monogr 221–6
18.
Zurück zum Zitat Saeter G, Elomaa I, Wahlqvist Y, Alvegård TA, Wiebe T, Monge O, et al. (1997) Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 273:156–160CrossRefPubMed Saeter G, Elomaa I, Wahlqvist Y, Alvegård TA, Wiebe T, Monge O, et al. (1997) Prognostic factors in bone sarcomas. Acta Orthop Scand Suppl 273:156–160CrossRefPubMed
19.
20.
Zurück zum Zitat Bacci G, Ferrari S, Sangiorgi L, Picci P, Casadei R, Orlandi M, et al. (1994) Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 6:204–210CrossRefPubMed Bacci G, Ferrari S, Sangiorgi L, Picci P, Casadei R, Orlandi M, et al. (1994) Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother 6:204–210CrossRefPubMed
21.
Zurück zum Zitat Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, et al. (2002) Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli institute. Oncol Rep 9:171–175PubMed Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, et al. (2002) Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli institute. Oncol Rep 9:171–175PubMed
22.
Zurück zum Zitat Chen J, Sun M-X, Hua Y-Q, Cai Z-D (2014) Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis. J Cancer Res Clin Oncol 0–5. doi:10.1007/s00432-014-1644-0 Chen J, Sun M-X, Hua Y-Q, Cai Z-D (2014) Prognostic significance of serum lactate dehydrogenase level in osteosarcoma: a meta-analysis. J Cancer Res Clin Oncol 0–5. doi:10.​1007/​s00432-014-1644-0
25.
Zurück zum Zitat Navalkele P, Jones SM, Jones JK, Salazar JD, Toy PC, Iyer RV, et al. (2013) Osteosarcoma tumor thrombus: a case report with a review of the literature. Tex Heart Inst J 40:75–78PubMedPubMedCentral Navalkele P, Jones SM, Jones JK, Salazar JD, Toy PC, Iyer RV, et al. (2013) Osteosarcoma tumor thrombus: a case report with a review of the literature. Tex Heart Inst J 40:75–78PubMedPubMedCentral
26.
Zurück zum Zitat Alvegard TA, Berg NO, Baldetorp B, Ferno M, Killander D, Ranstam J, et al. (1990) Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian sarcoma group experience. J Clin Oncol 8:538–547PubMed Alvegard TA, Berg NO, Baldetorp B, Ferno M, Killander D, Ranstam J, et al. (1990) Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian sarcoma group experience. J Clin Oncol 8:538–547PubMed
27.
Zurück zum Zitat Lack EE, Steinberg SM, White DE, Kinsella T, Glatstein E, Chang AE, et al. (1989) Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. J Surg Oncol 41:263–273CrossRefPubMed Lack EE, Steinberg SM, White DE, Kinsella T, Glatstein E, Chang AE, et al. (1989) Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas. J Surg Oncol 41:263–273CrossRefPubMed
28.
Zurück zum Zitat Gustafson P, Rydholm A, Willem H, Baldetorp B, Ferno M, Akerman M (1993) Liposarcoma: a population-based epidemiologic and prognostic study of features of 43 patients, including tumor DNA content. Int J Cancer 55:541–546. doi:10.1002/ijc.2910550404 CrossRefPubMed Gustafson P, Rydholm A, Willem H, Baldetorp B, Ferno M, Akerman M (1993) Liposarcoma: a population-based epidemiologic and prognostic study of features of 43 patients, including tumor DNA content. Int J Cancer 55:541–546. doi:10.​1002/​ijc.​2910550404 CrossRefPubMed
31.
Zurück zum Zitat Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, et al. (2011) A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer 117:1279–1287. doi:10.1002/cncr.25621 CrossRefPubMed Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, et al. (2011) A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer 117:1279–1287. doi:10.​1002/​cncr.​25621 CrossRefPubMed
Metadaten
Titel
Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas
verfasst von
Sarah Benezech
Sylvie Chabaud
Fanny Chambon
Frédérique Dijoud
Franck Chotel
Perrine Marec-Berard
Publikationsdatum
26.05.2016
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 4/2016
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0074-5

Weitere Artikel der Ausgabe 4/2016

Pathology & Oncology Research 4/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.